Musculoskeletal disorders in patients with stable coronary artery disease

Aim . To determine the prevalence of aberrant musculoskeletal status (MSS) variants among patients with stable coronary artery disease (CAD) and to evaluate their paraclinical characteristics. Material and methods . Clinical and paraclinical from 160 patients with stable CAD treated at the Kemerovo Research Institute for Complex Issues of Cardiovascular Diseases were analyzed. The mean age of patients was 67 years (62,5; 73). The most common comorbidities included hypertension (n=152 (95%)), diabetes mellitus (n=46 (28,7%)), heart failure (n=160, (100%)), and chronic kidney disease (n=111 (69,4%)). Sarcopenia was verified according to the consensus of the European Working Group on Sarcopenia in Older People 2 (2019). The basis for establishing such pathology as osteoporosis and osteopenia were the t-test values in accordance with the current federal clinical guidelines. In the case of a combination of osteoporosis/osteopenia and sarcopenia, the condition was assessed as osteosarcopenia. R e sults . Patients with intact MSS were predominantly men; the group with aberrant MSS was predominantly women, which, naturally, was accompanied by shorter height, weight, and body mass index. No differences in the prevalence of comorbidities were observed. Paraclinical investigations revealed that patients with musculoskeletal system abnormalities had lower hemoglobin levels, activated partial thromboplastin time, and international normalized ratio, higher platelet counts, and lower dynamometry, musculoskeletal index, and femoral neck t-score values. Conclusion . Aberrant MSS is a fairly common pathology in patients with CAD, occurring in more than half of cases. Osteopenia is the most common pathology (68,8%), equally distributed among men and women. Osteoporosis and osteosarcopenia are observed in 13,3% and 16,8% of cases, respectively. Accordingly, isolated sarcopenia occurs in only 1,1%. MSS pathology is associated with older age, female sex (except for osteopenia), and lower height and weight.